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Objectives: Asbestos-related diseases (ARDs) have increased globally over the decades, causing an economic burden and in-
creased health care costs. It is difficult to predict the risk of development of ARDs and of respiratory disability among workers 
with a history of asbestos exposure. Blood based biomarkers have been reported as promising tools for the early detection of 
malignant mesothelioma. This study investigated whether serum soluble mesothelin-related peptide (SMRP) would reflect sever-
ity of disablement in compensable ARDs.
Methods: SMRP levels were measured in a cohort of 514 asbestos-exposed subjects. Severity of ARDs was assessed by a Medical 
Authority comprising four specially qualified respiratory physicians. Severity of ARDs and SMRP levels were compared.
Results: Mean (standard deviation) serum SMRP level in the population with compensable ARDs (n = 150) was 0.95 (0.65) nmol/
L, and was positively associated with disability assessment (p = 0.01). Mean SMRP level in healthy asbestos-exposed subjects was 
significantly lower than those with pleural plaques (p < 0.0001) and in subjects with ARDs who received compensation (p < 0.01).
Conclusion: This study indicates that serum SMRP levels correlate with severity of compensable ARDs. Serum SMRP could poten-
tially be applied to monitor progress of ARDs. Further prospective work is needed to confirm the relationship between SMRP and 
disability assessment in this population.
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Introduction
Asbestos is a carcinogenic substance [1], which causes ma-
lignant mesothelioma (MM) and lung cancer. It also induces 
benign diseases, such as pleural plaques, asbestosis, and diffuse 
pleural thickening. These diseases, simply called asbestos-relat-
ed diseases (ARDs) are well described and the annual death at-
tributable to asbestos exposure is estimated to be approximately 
107,000 worldwide [2]. Compensation costs in the USA and 
Europe in the next decade are estimated at USD 280 billion [3]. 
If ARDs could be detected in their early stages, they might 
be managed and treated more effectively. MM, in particular, 
has no cure, but novel treatments are under development and 
early detection might eventually prove helpful in controlling 
this neoplasm [3,4]. Blood based biomarkers, such as soluble 
mesothelin-related peptide (SMRP), have been reported to be 
useful in the differential diagnosis and in monitoring the prog-
ress of epithelial type MM, but not for early detection [5-10]. 
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There are several studies that have suggested that an elevated 
serum SMRP level is also related to the duration of  past as-
bestos exposure [10,11], although contrary findings have also 
been reported [8], possibly due to the difficulty in quantifying 
asbestos exposure [12]. If  SMRP can be used as a surrogate for 
past asbestos exposure, this might be helpful in predicting the 
severity of disablement because the risk of these disease devel-
opments is related to cumulative asbestos exposure [13].
To date, the relationship between SMRP level and degree 
of severity of ARDs has not been investigated. Therefore, the 
aim of  this study was to assess whether serum SMRP levels 
reflect disablement assessment and severity of ARDs. 
Materials and Methods
Study population
These data are derived from a cohort population, which has 
been previously described [7]. In brief, the study was con-
ducted at the Workers’ Compensation (Dust Diseases) Board 
(DDB) of  New South Wales, Sydney, Australia. This study 
was approved by the Human Research Ethics Committee of 
St. Vincent’s Hospital, Sydney, Australia. All participants pro-
vided written informed consent followed by blood collection 
and they were not compensated for their participation. Serum 
samples were stored at -80oC until analysis. A routine medical 
examination for asbestos-exposed workers conducted at the 
DDB included a standardized questionnaire, a clinical exami-
nation by a thoracic physician, a chest radiograph, a computed 
tomography (CT) scan if  indicated, and full lung function tests. 
Subjects were categorized into 5 diagnostic groups according to 
the American Thoracic Society criteria [14].
Compensation scheme and assessment of disability 
Under the Workers’ Compensation (Dust Diseases) Act 1942, 
workers who had occupational asbestos exposure as an em-
ployee in New South Wales, Australia, are eligible to apply for 
compensation to the DDB. The Medical Authority (MA) at the 
DDB consists of  a panel of  four respiratory physicians. The 
MA certifies that an individual has an ARDs and is entitled 
to compensation after a consideration of occupational history, 
radiological evidence, lung function test results, and (where 
required) the caring respiratory physician’s medical report. 
The severity of compensable ARDs is measured as a percent-
age respiratory disability between 0% and 100%, based on 
American Medical Association (AMA) IV criteria [15]. These 
criteria are based on symptoms, lung function tests and, where 
necessary, further tests. Respiratory disablement was classified 
into 4 different classes (0-9%, 10-25%, 26-50%, and 51-100%). 
MM and lung cancer due to asbestos exposure are always as-
sessed as having 100% respiratory disablement. Non-malignant 
occupational respiratory disorders are assessed according to 
symptoms, lung function test results, and radiological findings. 
Subjects awarded compensation are entitled to a regular pen-
sion and their disablement assessment is reassessed approxi-
mately every two years on the basis of repeat examinations and 
investigations. 
SMRP measurement 
Serum SMRP levels were determined using the commercial 
ELISA kit (Mesomark; Fujirebio Diagnostics Inc., Malvern, 
PA, USA) according to the manufacturer’s instructions, and 
results were expressed in nmol/L. The limit of detection (LOD) 
for SMRP assay was 0.3 nmol/L. Samples less than LOD were 
reported as 0.3 nmol/L for statistical purposes. Assays were 
performed in duplicate and in blinded fashion at a single labo-
ratory.
Statistical analysis 
The association between SMRP levels and degree of severity of 
ARDs were determined using analysis of variance (ANOVA), 
chi-square test, Pearson regression, and the Students’ t-test. A 
Bonferroni correction was applied for multiple comparisons in 
post hoc tests. Statistical analyses were performed in GraphPad 
Prism (version 5; Graphpad Software, San Diego, CA, USA). 
A p-value less than 0.05 was considered significant. 
Results
Study population 
The study population has been previously described [7]. Briefly, 
study participants (n = 514) were categorized into 5 diagnostic 
groups: asbestosis (n = 24), diffuse pleural thickening (DPT) 
(n = 113), asbestosis and DPT (n = 13), pleural plaques (PPs) 
only (n = 141), and apparently healthy subjects with past asbes-
tos exposure (n = 223). Mean age (stnadard deviation, SD) of 
this population (n = 514) was 66.9 (10.1) years. A total of 150 
subjects were diagnosed with asbestosis, DPT, and asbestosis + 
DPT by the MA which are the compensable ARDs. Of these, 
81 subjects were deemed disabled due to their disease and had 
respiratory disablement assessed as between 10-100% and they 
were thus eligible for compensation (Table 1). Sixty-nine sub-
jects were assessed as 0% disability although ARDs were diag-
nosed. There was no statistical difference in age or body mass 
index between the two groups of  subjects with compensable 
ARDs; however, the group with compensated ARD had sig-
nificantly more ex-smokers than those with non-compensated 
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ARDs (p < 0.0001). 
SMRP measurements
Mean (SD) serum SMRP level in the population with compen-
sable ARDs (0-100%, n = 150) was 0.95 (0.65) nmoL/L. A sig-
nificant positive correlation between SMRP level and severity 
of compensable ARDs (0-100%, n = 150) was found (Pearson r 
= 0.209, p = 0.01, Fig. 1). 
Mean (SD) serum levels of  SMRP differed between the 
four groups; 1) subjects with a history of  asbestos exposure 
but apparently healthy (n = 223, 0.79 [0.45] nmoL/L); 2) 
subjects with PPs (n = 141, 1.00 [0.60] nmoL/L); 3) subjects 
who were diagnosed with compensable ARDs but were not 
awarded compensation due to their 0% disability (n = 69, 0.82 
[0.46] nmoL/L); and 4) subjects who received compensation 
due to their 10-100% disability (n = 81, 1.06 [0.76] nmoL/L) 
(ANOVA, p < 0.0001, Fig. 2). Mean SMRP level in the healthy 
subjects was significantly lower than in subjects with PPs (p < 
0.01) and in subjects who were entitled to compensation due to 
Table 1. Basic characteristics of study subjects by group
Healthy asbestos-exposed 
population (n = 223)
Pleural plaques
(n = 141)
Non compensated ARDs*  
(n = 69)
Compensated ARDs*  
(n = 81)
Age, mean (standard deviation), 
  year
61.2 (10.2) 69.7 (8.7) 70.7 (7.3) 73.2 (6.2)
Body mass index, % (n)
  < 18.5
  18.5-24.9
  25-29.9
  ≥ 30
0.5 (1)
20.6 (46)
48.9 (109)
30.1 (67)
0.7 (1)
24.1 (34)
51.1 (72)
24.1 (34)
0 (0)
13.0 (9)
53.6 (37)
33.3 (23)
1.2 (1)
11.1 (9)
59.3 (48)
28.4 (23)
Smoking status, % (n) 
  Never-smoker
  Ex-smoker
  Current-smoker
46.6 (104)
42.6 (95)
10.8 (24)
35.9 (51)
56.0 (79)
7.8 (11) 
18.8 (13)
5.8 (4)
75.4 (52)
23.5 (19)
72.8 (59)
3.7 (3)
ARDs: asbestos-related diseases. 
*ARDs include asbestosis, diffuse pleural thickening (DPT), and asbestos/DPT. Entitlement of compensation is based on severity of ARDs from 
0-100%. 
Fig. 1. Association between SMRP concentration and disablement 
due to asbestos-related diseases as assessed by the Medical Authority 
(n = 150, Pearson r = 0.209, p = 0.01). SMRP: soluble mesothelin-
related peptide. Fig. 2. SMRP concentration in subjects. (1) Exposed to asbestos but 
apparently healthy, (2) with pleural plaques, (3) with asbestos-related 
diseases (includes asbestosis, diffuse pleural thickening [DPT] and 
asbestosis/DPT) but not eligible for compensation due to their 0% 
disablement, (4) with compensated asbestos-related diseases due 
to their 10-100% disablement. Horizontal scale bars denote mean 
concentrations. There was a significant difference between the groups 
(analysis of variance, p < 0.0001). SMRP: soluble mesothelin-related 
peptide, ARDs: asbestos-related diseases.
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their 10-100% disability (p < 0.01). 
Discussion
Our study has demonstrated a relationship between disable-
ment from non-malignant ARDs (as assessed according to 
AMA criteria) and a blood biomarker, SMRP. This is not 
unexpected because disablement is awarded to those who are 
suffering from an established disease due to asbestos and who 
are symptomatic, and is strongly linked to a severity of the dis-
eases, which in turn is related to previous cumulative exposure 
to asbestos. Severity of  disability, as determined by the MA 
using AMA V criteria [15], takes into account the symptoms, 
lung function, and radiological change, but is highly reliant on 
lung function. Mean (SD) serum levels of SMRP differed be-
tween four groups examined and the mean SMRP level in the 
healthy subjects was significantly lower than in subjects who 
were entitled to compensation due to their 10-100% disability 
(p < 0.01). Thus, SMRP, which is an entirely objective marker, 
seems likely to reflect different stages or severity of ARDs and 
could potentially be used for monitoring progress or disable-
ment assessment in ARDs. To our knowledge, this is the first 
report of such an association.
Asbestos usage has declined substantially in the Western 
world over the last four decades, but ARDs are predicted to 
increase due to the long latency period for development of the 
disease [13,16,17]. New technologies and increasing awareness 
of the adverse health effects of asbestos exposure are also likely 
to increase the diagnosis of these diseases. Thus, it is likely that 
the measurable prevalence of ARDs will increase over the next 
decades. Improvements in diagnostic methods (including blood 
biomarker usage) are also likely to occur. Although improve-
ment in diagnostic methodologies have allowed earlier diagno-
sis of benign ARDs, such as pleural plaques, it is still difficult to 
diagnose MM in its early stages [4]. Accurate non-invasive tests 
for asbestos-related malignancies would be of considerable clin-
ical benefit. Several biomarkers have been suggested for MM 
detection in its early stages and SMRP has received significant 
research attention [5-10,12]. However, biomarker analysis has 
not yet been applied to the assessment of disease severity or to 
compensation status. 
Along with diagnostic studies, several recent reports have 
investigated the association between SMRP levels and past his-
tory of asbestos exposure [8,9,11,12]. These studies were not 
uniform in their findings. Pass et al. did not find an association 
between SMRP and duration of  past asbestos exposure [8] 
but others found a significant relationship [9,11]. In these later 
studies, higher levels of serum SMRP were significantly related 
to the duration of past asbestos exposure. 
Overall, the development of ARDs is related to duration 
of  asbestos exposure in most populations, probably because 
this is a surrogate for intensity of exposure [13]. Disablement 
severity is assessed on the basis of symptoms as well as objec-
tive measures, such as lung function testing, and usually reflects 
an established disease that is more severe and thus highly likely 
to be related to past intensity of asbestos exposure. Thus, it is 
expected that SMRP would be related to the severity of disease 
and therefore to disablement status. It was not possible for us 
to assess past asbestos exposure in our study because of incom-
plete previous occupational exposure history records of the pre-
vious occupational exposure history in our cohort population. 
However, this would ideally be performed using an evidence-
based methodology, such as a standardized questionnaire and 
an occupational exposure matrix [18]. 
There are several potential confounding factors in our 
study. The population was derived from a compensation and 
screening registry, and it is therefore biased to include those 
with symptomatic diseases. Our findings are not reflective of 
the population in general, and in particular, for those with 
ARDs who do not apply for compensation. All our study sub-
jects were men. Smoking habits differered between the groups. 
Interestingly, SMRP levels in subjects with PPs were similar 
to those with compensable disease. The reasons for this are 
uncertain, but it is possible that some patients with PPs also 
had other ARDs, particularly asbestosis and/or DPT. High 
resolution CT scans are required for diagnosis and assessment 
in such cases, but these were not always available in our study. 
Currently, PPs alone (or with chest pain) are not accepted for 
compensation in the absence of other ARDs, as they are not 
associated with lung function abnormalities [19,20], although 
this has been questioned [21].
Lung function measurements were performed as part of 
an assessment for compensation, and it is possible that this 
could have confounded the results. We have previously found 
an association between lung function and SMRP levels [22], al-
though the mechanism for this is unclear. It would be expected 
that SMRP would reflect severity if  this were the case. How-
ever, it is also possible that SMRP reflects an inflammatory or 
another process which has been activated by asbestos exposure 
and which eventually results in an established disease. If SMRP 
or other biomarkers are found to be an accurate reflection of 
disablement, this could be helpful in providing an objective 
method of assessment. Further prospective work is needed in 
this area to substantiate our findings and clarify the underlying 
pathophysiological mechanisms of raised SMRP after asbestos 
exposure. 
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